Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Trovafloxacin. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHA2 | P29317 | 1/20 | 1.00 |
| ▸ | FLT4 | P35916 | 1/20 | 1.00 |
| ▸ | GSK3B | P49841 | 1/20 | 1.00 |
| ▸ | RARB | P10826 | 1/20 | 1.00 |
| ▸ | TBXAS1 | P24557 | 1/20 | 1.00 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 1.00 |
| ▸ | LMNA | P02545 | 4/20 | 0.90 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.90 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.90 |
| ▸ | HPGD | P15428 | 2/20 | 0.90 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.90 |
| ▸ | POLB | P06746 | 2/20 | 0.90 |
| ▸ | XBP1 | P17861 | 1/20 | 0.90 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.90 |
| ▸ | HTT | P42858 | 1/20 | 0.90 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.90 |
| ▸ | RELA | Q04206 | 1/20 | 0.90 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.77 |
| ▸ | DPP4 | P27487 | 6/20 | 0.55 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Trovafloxacin SCHEMBL1902266 | 1.00 | EPHA2 (1.00) | EPHA2FLT4GSK3BRARBTBXAS1 | |
| Trovafloxacin SCHEMBL34465 | 1.00 | EPHA2 (1.00) | EPHA2FLT4GSK3BRARBTBXAS1 | |
| Trovafloxacin SCHEMBL20769811 | 1.00 | EPHA2 (1.00) | EPHA2FLT4GSK3BRARBTBXAS1 | |
| Trovafloxacin SCHEMBL13575805 | 1.00 | EPHA2 (1.00) | EPHA2FLT4GSK3BRARBTBXAS1 | |
| Trovafloxacin SCHEMBL34466 | 1.00 | EPHA2 (1.00) | EPHA2FLT4GSK3BRARBTBXAS1 | |
| Trovafloxacin SCHEMBL29384064 | 1.00 | EPHA2 (1.00) | EPHA2FLT4GSK3BRARBTBXAS1 | |
| Trovafloxacin SCHEMBL9177464 | 1.00 | EPHA2 (1.00) | EPHA2FLT4GSK3BRARBTBXAS1 | |
| Trovafloxacin SCHEMBL29711175 | 0.99 | EPHA2 (0.98) | EPHA2FLT4GSK3BRARBTBXAS1 | |
| Trovafloxacin SCHEMBL1229029 | 0.99 | EPHA2 (0.98) | EPHA2FLT4GSK3BRARBTBXAS1 | |
| Trovafloxacin SCHEMBL7688504 | 0.99 | EPHA2 (0.98) | EPHA2FLT4GSK3BRARBTBXAS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240382506-A1 | Means and Methods to Regulate Gut Dysbiosis | UNIVERSITEIT GENT (BE) | 2024-11-21 | — | — | US | disclosed |
| EP-4355877-A1 | MEANS AND METHODS TO REGULATE GUT DYSBIOSIS | VIB VZW (BE) | 2024-04-24 | — | — | EP | disclosed |
| WO-2022263678-A1 | MEANS AND METHODS TO REGULATE GUT DYSBIOSIS | VIB VZW (BE) | 2022-12-22 | — | — | WO | disclosed |
| US-20220226310-A1 | Bio-Based Medicines and Methods of Increasing Patient Compliance | RDE PHARMA | 2022-07-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220226310-A1 | Bio-Based Medicines and Methods of Increasing Patient Compliance | PAH, BPGM, TPMT | EPHA2 3121/4885FLT4 2133/4885GSK3B 2289/4885 |
| US-20240382506-A1 | Means and Methods to Regulate Gut Dysbiosis | SI, FABP2, PDK1 | EPHA2 4341/4885FLT4 1465/4885GSK3B 177/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.